Werewolf Therapeutics, Inc.
HOWL
$0.86
-$0.06-6.20%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 1,016.55% | -92.10% | |||
| Gross Profit | -1,016.55% | 92.10% | |||
| SG&A Expenses | -6.05% | -8.83% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.35% | -2.50% | |||
| Operating Income | 10.35% | 2.50% | |||
| Income Before Tax | 8.96% | 0.59% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 8.96% | 0.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 8.96% | 0.59% | |||
| EBIT | 10.35% | 2.50% | |||
| EBITDA | 10.57% | 2.44% | |||
| EPS Basic | 10.61% | 0.92% | |||
| Normalized Basic EPS | 10.60% | 0.91% | |||
| EPS Diluted | 10.00% | 0.87% | |||
| Normalized Diluted EPS | 10.60% | 0.91% | |||
| Average Basic Shares Outstanding | 1.83% | 0.34% | |||
| Average Diluted Shares Outstanding | 1.83% | 0.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||